New­ly-pub­lic Im­muno­vant an­nounces first proof-of-con­cept suc­cess

Im­muno­vant an­nounced its first batch of proof-of-con­cept da­ta for its an­ti­body against a rare au­toim­mune dis­ease, a month af­ter its biggest ri­val slid one of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER